SeaBeLife

Human liver
#European Medicines Agency #Liver disease #Orphan drugs #Rare disease #SeaBeLife

Orphan drug prevents cell death in acute liver failure

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). ALF occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver… Read More

#News